Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Dr. Alaina Jaster speaks with Dr. Mark Geyer in a discussion that traces his path to psychedelics research, the field’s scientific and cultural shifts, and the role of the Heffter Research Institute. He also reflects on therapeutic models, potential risks of backlash, and the importance
of education in expanding access.
Q2’25 Psychedelic Lobbying Update • Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find • UK Moves Toward Easing Schedule I Research Restrictions But Keeps Industry at Arm’s Length • “Shell Games” and Whistleblowers: MassGOP Goes on Offensive Against Psychedelics Campaigners • Aussie University Seeks Public Comments on MDMA Clinical Practice Guideline • and more..
Psychedelic Alpha’s Charles Bliss speaks with Professor Celia Morgan, a leading ketamine researcher, about the promise of ketamine-assisted therapy for alcohol use disorder, rising concerns over recreational abuse, and her thoughts on proposals to reclassify the drug in the UK.
AbbVie Eyes Billion-Dollar Gilgamesh Acquisition • What Is Kyrsten Sinema Selling? • Compass ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program • Psychedelics Industry’s Input on EMA’s Draft Depression Guideline • National Survey Reveals Psychedelics Use Again Rises in US • FDA Moves to Ban Kratom Compound 7-OH • Compass Talks Accelerated Approval on Q2’25 Earnings Call • atai All-In on Psychedelics Following RL-007 Flop • UK Government Publishes Life Sciences Plan • NMDA or Opioid? Ketamine’s True Target Under Scrutiny • Budget, Dosing, and Paperwork Raised at OPS Listening Sessions • and more..
Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany’s model empowers clinicians to decide on patient eligibility without case-by-case regulatory approval and might succeed in having insurers cover much of the cost. Here, we speak with one of the program’s key architects, Gerhard Gründer.
In this second Dispatch from the inaugural Neurobiology of Psychedelics Gordon Research Conference, Dr. Alaina Jaster recaps Days 2 through 4, highlighting cutting-edge research on neuroplasticity, animal cognition, drug discovery, clinical studies, and altered states of consciousness. Featured speakers include Linda Simmler, David Erritzoe, Jennifer Mitchell, and many more.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from January 5 – June 1, 2025
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
This is an archived version of our Psychedelic News Feed, from February 5 2024 – March 3 2024.
This is an archived version of our Psychedelic News Feed, from January 8 2024 – February 4 2024.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
